(S)-1-(4-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)phenyl)ethanamine | 447460-03-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-1-(4-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)phenyl)ethanamine
• 英文别名: (1S)-1-[4-[4-chloro-2-(2-fluorophenyl)sulfonylphenyl]sulfonylphenyl]ethanamine
• CAS: 447460-03-9
• 化学式: C₂₀H₁₇ClFNO₄S₂
• 分子量: 453.943
• InChiKey: BNYQCLBSRNFGPY-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-1-(4-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)phenyl)ethanamine 在 sodium hydroxide 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (S)-trifluoro-N-(1-(4-(2-(2-fluorophenylsulfonyl)-4-(2-methoxyethoxy)phenylsulfonyl)phenyl)ethyl)methanesulfonamide
  参考文献：
  名称：

  Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands

  摘要：

  Structure-activity relationship on our recently reported triaryl bis-sulfone class of cannabinoid-2 (C132) receptor selective inverse agonists was explored. Modifications to the methane sulfonamide, substitutions to B and C phenyl rings, and replacements of the C-ring were investigated. A compound with excellent C132 activity, selectivity for C132 over CB I, and in vivo plasma levels was identified. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.028
• 作为产物：
  描述：

  N-{1-[4-(4-chlorobenzenesulfonyl)-phenyl]ethyl}-2,2,2-trifluoroacetamide 在 正丁基锂 、 lithium 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 为溶剂， 反应 1.0h， 生成 (S)-1-(4-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)phenyl)ethanamine
  参考文献：
  名称：

  Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies

  摘要：

  We recently reported that compound 1 is a potent inhibitor of the CB2 receptor with high selectivity over CB1. This paper describes the SAR development for this class of compounds. Variation of the substitution pattern on the aromatic rings, as well as the groups linking them together, led to sub-nanomolar inhibitors of the CB2 receptor, with high selectivity over CB1. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.023

文献信息

• Cannabinoid receptor ligands
  申请人：Schering Corporation

  公开号：US20030232859A1

  公开（公告）日：2003-12-18

  The invention relates to compounds of the formula 1 a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds and methods of using the compounds for the treatment of various diseases and conditions.

  这项发明涉及以下化合物的公式 1 其前药，或该化合物或前药的药用可接受的盐、溶剂合物或立体异构体；这些化合物表现出抗炎和免疫调节活性。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗各种疾病和病况的方法。
• US7507767B2
  申请人：——

  公开号：US7507767B2

  公开（公告）日：2009-03-24
• US7718702B2
  申请人：——

  公开号：US7718702B2

  公开（公告）日：2010-05-18